Effects of Treatment Modalities for Graves’ Hyperthyroidism on Graves’ Orbitopathy: A 2015 Italian Society of Endocrinology Consensus Statement - oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Guides & Guidelines

Effects of Treatment Modalities for Graves’ Hyperthyroidism on Graves’ Orbitopathy: A 2015 Italian Society of Endocrinology Consensus Statement

key information

source: Journal of Endocrinological Investigation

year: 2015

authors: Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F

summary/abstract:

Graves’ disease is the most frequent form of hyperthyroidism in iodine sufficient countries, and Graves’ orbitopathy (GO) is its most important and common extrathyroidal manifestation, affecting about 25 % of patients. Although GO is generally mild and rarely progressive, thyroid dysfunction, both hyperthyroidism, and hypothyroidism, can influence its course. GO has been reported to improve after correction of hyperthyroidism with antithyroid drug (ATD) treatment, or to occur or worsen after a period of uncontrolled hypothyroidism.

Accordingly, the European Group on Graves’ Orbitopathy (EUGOGO) Consensus Statement few years ago recommended that restoration and maintenance of euthyroidism are priorities in Graves’ disease patients with GO. How to treat hyperthyroidism when GO is present is, however, a challenging dilemma. Are current modalities for hyperthyroidism [ATDs, radioiodine (RAI), thyroidectomy] per se capable to affect the course of GO? If orbital disease is present, is it preferable to control hyperthyroidism with ATDs or may thyroid ablation (RAI, thyroidectomy, alone or in association) be advantageous by removing factors (thyroid autoreactive lymphocytes, thyroid antigens) that may promote the occurrence and/or progression of GO?

organization: University of Insubria, Italy; University of Naples "Federico II”, Italy; University of Pisa, Italy; University of Milan, Italy; University of Messina, Italy

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

© 2022 rareLife solutions Inc.